ProQR Therapeutics announces a Phase 1 trial of AX-0810 to evaluate safety and target engagement in cholestatic liver disease. The initiation of the Phase 1 clinical trial for AX-0810 is contingent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback